Page 1

13 January 2021 Financial Summary ● Kromek ( AIM : KMK ) , a worldwide supplier of detection technology focusing on the medical , security screening and nuclear markets , announces its interim results for the six months ended 31 October 2020 . ● ● ● ● ● Kromek Group plc ( " Kromek " or the " Group " ) Interim Results * Adjusted EBITDA is defined as earnings before interest , taxation , depreciation , amortisation , other income and share - based payments . For further details , see the Financial Review below . ● Revenue of £ 4.6m ( H1 2019/20 : £ 5.3m ) Operational Summary Resumption of orders and shipments across all segments in final two months of the period with business patterns starting to return to normal and increased commercial activity post period Continuing commercial traction and development of D3S family of products , which has been sold in over 25 countries O Expansion of global footprint with sales commencing in a new country and engagement of five new distributors O Continued to supply products to Irish Civil Defence following contract win in 2019/20 Launch of next - generation D3 PRD and D5 RIID high - performance radiation detectors Nine new customers won in the civil nuclear segment and continued sales through distribution channels Significant progress in fast - growing bio - security market ● kromek detect image identify Gross margin was 54 % ( H1 2019/20 : 58 % ; FY 2019/20 : 47 % ) Adjusted EBITDA * was £ 0.9m loss ( H1 2019/20 : £ 0.6m loss ) Loss before tax was £ 3.4m ( H1 2019/20 : £ 2.7m loss ) Cash and cash equivalents at 31 October 2020 were £ 5.8m ( 30 April 2020 : £ 9.4m ; 31 October 2019 : £ 13.4m ) O Awarded $ 5.2m contract extension by the Defense Advanced Research Projects Agency ( " DARPA " ) , an agency of the US Department of Defense , to advance the development of a mobile wide - area bio - security system capable of detecting and identifying airborne pathogens O Building field deployable systems to detect presence of pathogens in high footfall areas such as hospitals , mass transport hubs and entertainment venues Extended medical application for CZT - based detectors from cancer diagnosis to cancer surgery through new R & D project with Adaptix Ltd and the University of Manchester Current Trading and Outlook Entered H2 2020/21 with extensive commercial pipeline and experiencing rebound in commercial activity Received first commercial order from security screening OEM customer following achievement of highest level of European liquid explosive detection certification for cabin baggage for its scanner Four new patents were filed and five were granted during the period O O OEM customer that awarded $ 58.1m contract has commenced the installation , in multiple countries , of its medical imaging devices for the early detection of cardiovascular diseases . The rollout is expected to ramp - up from H2 2020/21 Two contract extensions for networked radiation detection technologies with a European government - related customer - a key step towards customer's full wide - area system rollout O Secured new sector - leading global OEM customer for development of customised detectors for industrial applications ; expected to transition into multi - year supply contract Bio - security activity to accelerate with airport and hospital piloting of pathogen detection platform expected to commence in H2 2020/21 ● Increased trading and improved visibility gives confidence of significant revenue growth in H2 2020/21 as compared to H1 2020/21 Dr Arnab Basu , CEO of Kromek , said : “ I am pleased to report that we finished the first half of 2020/21 in a stronger position than we entered the year , resulting from a considerable uptick in trading in the last two months of the period . We are starting to see a return to some normality in business patterns as our customers recommence their commercial activities . In particular , our largest medical OEM customer has